U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
Takeda Pharmaceutical Company Limited U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treat Saturday, May 22, 2021 10:31AM IST (5:01AM GMT) Osaka, Japan: − If Approved, Maribavir Will Be the First and Only Treatment Indicated for Post-Transplant Cytomegalovirus (CMV) Infecti...
United States Fred Hutch Michael Boeckh Ryoko Matsumoto Maribavir Global Program Leader Human Cytomegalovirus Nuclear Egress
Source: businesswireindia.com